Authors
Augusto Villanueva, Derek Y Chiang, Pippa Newell, Judit Peix, Swan Thung, Clara Alsinet, Victoria Tovar, Sasan Roayaie, Beatriz Minguez, Manel Sole, Carlo Battiston, Stijn Van Laarhoven, Maria I Fiel, Analisa Di Feo, Yujin Hoshida, Steven Yea, Sara Toffanin, Alex Ramos, John A Martignetti, Vincenzo Mazzaferro, Jordi Bruix, Samuel Waxman, Myron Schwartz, Matthew Meyerson, Scott L Friedman, Josep M Llovet
Publication date
2008/12/1
Journal
Gastroenterology
Volume
135
Issue
6
Pages
1972-1983. e11
Publisher
WB Saunders
Description
BACKGROUND & AIMS
The advent of targeted therapies in hepatocellular carcinoma (HCC) has underscored the importance of pathway characterization to identify novel molecular targets for treatment. Based on its role in cell growth and differentiation, we evaluated mTOR signaling activation in human HCC, as well as the antitumoral effect of a dual-level blockade of the mTOR pathway.
METHODS
The mTOR pathway was assessed using integrated data from mutation analysis (direct sequencing), DNA copy number changes (SNP-array), messenger RNA levels (quantitative reverse-transcription polymerase chain reaction and gene expression microarray), and protein activation (immunostaining) in 351 human samples, including HCC (n = 314), and nontumoral tissue (n = 37). The effects of dual blockade of mTOR signaling using a rapamycin analog (everolimus) and an epidermal growth factor receptor/vascular …
Total citations
Scholar articles
A Villanueva, DY Chiang, P Newell, J Peix, S Thung… - Gastroenterology, 2008